Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Official Title

A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

Summary:

NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: - The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care - The combination of NUC-1031 plus cisplatin increases overall response rate compared to the gemcitabine plus cisplatin standard of care

Trial Description

Primary Outcome:

  • Overall survival (OS)
  • Objective response rate (ORR)
Secondary Outcome:
  • Progression-free survival (PFS)
  • Duration of response (DoR)
  • 12-month survival
  • 18-month survival
  • Disease control rate (DCR)
  • Safety and tolerability
  • Maximum observed plasma concentration (Cmax) of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only
  • Area under the plasma concentration-time curve (AUC) of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only
  • Elimination half-life (t½) of NUC-1031, dFdC and dFdU using descriptive statistics in Arm A only
  • Terminal elimination rate constant (λz) of NUC-1031, dFdC and dFdU using descriptive statistics in Arm A only
  • Clearance of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only
  • Volume of distribution of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only
  • Comparison of patient-reported quality of life (QoL) scores in Arm A and Arm B
  • Comparison of patient-reported quality of life (QoL) scores in Arm A and Arm B

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society